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Endothelin-1 (ET-1), known as a potent vasoconstrictor, has been
implicated in pathogenesis of osteoarthritis (OA). ET-1 could induce
matrix metalloproteinase 13 (MMP13) expressions by chondrocytes in
vitro. Use of Endothelin 1 receptor A antagonist,might rescueOA inmice.
Yet the direct evidence remains lackingwhether overexpressed ET-1will
lead to development of OA. Therefore, we aim to characterize the
phenotypes of the articular cartilage and subchondral bone in a
transgenic endothelial cell-speciﬁc (Tie-1 promoter) overexpressed
endothelin-1 (TET-1) mice. Male heterozygous TET-1 mice were
generated by microinjection of the ET-1 construct, which contained the
mouse ET-1 cDNAwith SV40 polyA driven by the Tie-1 promoter. TET-1
mice developed systemic hypertension with altered vascular reactivity
since 8 weeks after birth. Tibiae of male, heterozygous TET-1 mice
(n= 4) and their non-transgenic littermates (n= 4) of 35-weeks-old
were obtained. PCRwere used to conﬁrm their genotypes.Micro-CT scan
on tibiaewere performed before tissue processed towax blocks. Tibiae in
wax blockswere sectioned and histologywas studied on 5 μm-thickwax
sections. Micro-CT data showed a decrease of bone volume/tissue
volume (BV/TV, 10.9 ± 0.4%) in TET-1 mice primary spongiosa when
compared to the age- and gender-matched littermates (12.8 ± 0.5%,
p b 0.05). In contrast, therewas no signiﬁcant difference in the density of
subchondral trabecular bone (secondary spongiosa) between TET-1
mice (23.5 ± 3.6%) and their littermates (25.7 ± 1.4%, p N 0.05).It was
revealed histologically that articular chondrocytes underwent hypertro-
phic changes togetherwith thickening of calciﬁed cartilage in TET-1mice
as compared to their littermates. In summary, TET-1 mice present OA-
like changes and overexpression of ET-1 contributes to hypertrophic
changes of articular chondrocytes.
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Background: Endothelin-1 (ET-1) is strongly implicated in cardiac
and renal pathologies both as a potent vasoconstrictor and as an inducer
of tissue remodelling and ﬁbrosis. However, ET antagonists demonstrat-
ed limited efﬁcacy in clinical trials of heart failure and hypertension.
Thus, alternative preproendothelin-1 (ppET-1) derived peptides may
contribute/interact with vasoconstrictor responses. Our aim was to
characterise ppET-1 biosynthesis and to evaluate potential interactions
with ET-1 responses. Methods and results: A combination of speciﬁc
immunoassays and HPLCwere used to characterise ppET-1 processing in
conditioned media samples from human endothelial (EA.hy 926) and
epithelial (A549) cells. Endothelin-like Domain Peptide (ELDP, ppET-1
[93–166]) was identiﬁed by immunoassay with LTQ-Orbitrap mass
spectrometer conﬁrmation. Speciﬁc ELISA for ELDP showed its release
from primary cultures of human aortic endothelial cells, which
correlated with ET-1. Blood pressure responses were investigated in
anaesthetised rats. Although synthetic ELDP alone (3 nmol/kg) had no
effect, it signiﬁcantly increased the duration of the pressor response to
ET-1 (0.3 nmol/kg, p b 0.02). On rat mesenteric resistance arteries
(rMRA), ELDP alone had no signiﬁcant vasoconstrictor effect up to
10 nM, but after pre- treatment with ET-1 (1–3 nM) produced a
concentration-dependent vasoconstriction. Pre-incubation of rMRAwith
10 nM ELDP increased the response of 1 nM ET-1 by ~5-fold (p b 0.002).
Plasma levels of ELDP, measured by sandwich immunoassay, showed a
signiﬁcant difference between untreated subjects with pre-hyperten-
sion/mild hypertension (n = 24) compared to patients with chronic
heart failure (n= 24) (6.45 ± 0.19 and 7.80 ± 0.25 fmol/ml; p b 0.001,
respectively). Conclusions: ELDP is co-secretedwith ET-1 andmodulates
its vasoconstrictor responses. ELDPmay be a useful biomarker for EDN1-
linked pathologies.
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